Sugi Predict

Sugi Predict / Compounds / SCHEMBL147207

SCHEMBL147207

SCHEMBL147207

CCC(O)c1ccc(Br)cc1F

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 2/20 0.60
▸ APLNR P35414 4/20 0.41
▸ FPR2 P25090 1/20 0.39
▸ DGAT1 O75907 1/20 0.38
▸ POLB P06746 2/20 0.36
▸ LMNA P02545 1/20 0.35
▸ ADRA2A P08913 2/20 0.35
▸ ADRA2B P18089 2/20 0.35
▸ ADRA2C P18825 2/20 0.35
▸ ADRA1A P35348 2/20 0.35
▸ ADRB2 P07550 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11899944 0.86 PDE2A (0.45) PDE2AAPLNRFPR2DGAT1POLB
SCHEMBL182595 0.85 PDE2A (0.47) PDE2AFPR2DGAT1POLBLMNA
SCHEMBL8123783 0.84 PDE2A (0.44) PDE2AAPLNRFPR2DGAT1LMNA
SCHEMBL16070599 0.83 PDE2A (0.41) PDE2AAPLNRDGAT1LMNAADRA2A
SCHEMBL13470654 0.83 PDE2A (0.43) PDE2AAPLNRDGAT1LMNA
SCHEMBL13464609 0.82 PDE2A (0.42) PDE2AAPLNRLMNA
SCHEMBL15688137 0.81 PDE2A (0.40) PDE2AAPLNRDGAT1POLBLMNA
SCHEMBL17927648 0.81 PDE2A (0.44) PDE2AAPLNRDGAT1ADRA2AADRA2B
SCHEMBL7346953 0.80 ADRB2 (0.42) PDE2AAPLNRDGAT1ADRA2AADRA2B
SCHEMBL26161883 0.79 APLNR (0.45) PDE2AAPLNRFPR2DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
CN-115926807-A Liquid crystal medium and application 深圳市和力信材料有限公司 2023-04-07 — — CN disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 — — US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 — — EP disclosed
EP-2669270-B1 INDOLE-RELATED COMPOUNDS AS URAT1 INHIBITORS SATO PHARMA (JP) 2018-01-03 — — EP disclosed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 — — EP disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 — — US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 — — US disclosed
US-20140005221-A1 RING-FUSED COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2014-01-02 — — US disclosed
EP-2669270-A1 RING-FUSED COMPOUND Sato Pharmaceutical Co., Ltd. (JP) 2013-12-04 — — EP disclosed
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BAHMANYAR SOGOLE (US) 2013-01-03 — — US disclosed
US-8299056-B2 Aminotriazolopyridines, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC (US) 2012-10-30 — — US disclosed
WO-2012102405-A1 RING-FUSED COMPOUND 佐藤製薬株式会社 (JP) 2012-08-02 — — WO disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
EP-2344494-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS Signal Pharmaceuticals, LLC (US) 2011-07-20 — — EP disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2010-04-15 — — US disclosed
WO-2010027500-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2010-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 PDE2A 971/4885APLNR 3226/4885FPR2 3605/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PDE2A 935/4885APLNR 1539/4885FPR2 3688/4885
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 PDE2A 1822/4885APLNR 1967/4885FPR2 602/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PDE2A 935/4885APLNR 1539/4885FPR2 3688/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PDE2A 935/4885APLNR 1539/4885FPR2 3688/4885
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 PDE2A 1822/4885APLNR 1967/4885FPR2 602/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A PDE2A 921/4885APLNR 2011/4885FPR2 1119/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PDE2A 935/4885APLNR 1539/4885FPR2 3688/4885
US-20140005221-A1 RING-FUSED COMPOUND URB2, RCOR1, RCC2 PDE2A 805/4885APLNR 3971/4885FPR2 734/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PDE2A 935/4885APLNR 1539/4885FPR2 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.